

# CURRICULUM VITAE

## Dr. Stefano Ugel

**Born** at Oderzo (Italy); 24 March 1980

**Codice Fiscale:** GLUSFN80C24F999V

**Residence:** via 24 Maggio n° 20, Ormelle (TV) Italy

**Phone:** +39 0422 745497

+39 347 9010471

**email:** [sugel80@gmail.com](mailto:sugel80@gmail.com)

[stefano.ugel@univr.it](mailto:stefano.ugel@univr.it)

## EDUCATION

Dr. Stefano Ugel has 13 years (2003-2016) of laboratory experience. He started (2003-2004) as bachelor degree student in Biology at Department of Oncology and Surgical Science University of Padova with the thesis: "*Development of an efficient vaccination protocol towards p15E antigen in prostate tumor mouse model*" (108/110). After that he was selected for PhD-program in Oncology and Surgical Science, obtaining a PhD in 2008, with the thesis "*Active and passive immunotherapeutic approaches targeting Telomerase in mouse tumor models*". This program was carried out at the Department of Oncology and Surgical Science (Prof. P. Zanovello), University of Padova. From 2008, Dr Ugel has obtained a pluriennial post-doctoral fellowship: he won PhD fellowship "Volontari Comitato Veneto" (2008-2009) supported by AIRC to complete the project "*Generation of specific Telomerase cytotoxic T lymphocytes*" at Prof. Vincenzo Bronte laboratory (IOV - Istituto Oncologico Veneto - I.R.C.C.S); next he won a PhD fellowship to complete the project "*New anti-tumor drugs able to support a better intra-tumor lymphocytes infiltration*" (2009-Oct 2010) at Prof. Vincenzo Bronte laboratory (VIMM – Venetian Institute of Molecular Medicine, University of Padova). Successively, he won a PhD fellowship for Abroad (2010) supported by AIRC to complete the project "*TEM-1 positive cells: a new target for cancer immunotherapy*" as postdoctoral researcher in George Coukos' laboratory at Ovarian Cancer Research Center (ORCR) of University of Pennsylvania, 421 Curie Boulevard 19104 Philadelphia (PA) United States (USA). Then Dr. Ugel was integrated as PhD in the project DOD BRCA "*BRCA expression in ovarian cancer*" (rif. 553952) until May 2012. Then Dr. Ugel, as senior PhD, works at Immunology Section of Department of Medicine of Verona University, managed by Prof. Vincenzo Bronte (June 2012-2016). From November 2016, Dr. Ugel was enrolled as Tenure-track Assistant Professor at Department of Medicine, Immunology Section of University of Verona.

Dr. Stefano Ugel participated as Principal Investigator in the pre-selection stage of Futuro in Ricerca grant 2008, 2012 with the following projects: "*Microenvironment, cell plasticity and tumor development*" (rif. RBFR08AYDG\_003-2008) coordinated by Dr. Claudia Matteucci of Tor-Vergata University of Rome, "*Interaction between immune system and tumor: mechanisms of immunosuppression and strategies to restore immune fitness*" (rif: RBFR1211SR\_002-2012) coordinated by Dr. Chiara Napoletano of Sapienza University of Rome, that was overall evaluated

86/100. As coordinator, Dr. Stefano Ugel participated at last stage of Futuro in Ricerca grant 2013 with the project "A combined approach targeting functional markers of MDSCs and freshly identified cancer stem cells oncoantigens to improve a specific immunotherapy strategy in breast cancer" (rif: RBFR13IIM6-2013) that was overall evaluated 15.46 at second revision. Finally, Dr. Stefano Ugel, as coordinator, participated in Young Research Investigator Project 2013 by Ministero della Salute (Italy) with the project "Role of interferon-gamma in promoting graft-versus-host disease in allogeneic hematopoietic stem-cell transplantation recipients" (rif. GR-2013-02357093) that was overall evaluated 16 at revision.

## SCIENTIFIC ACTIVITY

Dr. Stefano Ugel research is based on:

- Validation of active immunotherapeutic approaches based on different vaccination setting using DNA plasmid in association with electric gene transfer, dendritic cells pulsed with cell-lysate or peptide, emulsinated peptide and also xenogenic vaccine
- Identification of immunodominant peptide of new tumor associated antigen.
- Validation of specific immune suppressive mechanisms in tumor tolerance.
- MDSC characterization in different tumor mouse models and human setting.
- Validation of passive immunotherapeutic approaches based on adoptive antigen specific CD8<sup>+</sup> T cell transfer and isolation of specific high avidity CTL.
- Validation of new drugs able to selectively eliminate cells with of regulatory abilities, such as MDSCs, to increase the efficacy of cancer immunotherapy.
- Validation of immunotherapeutic approaches able to attack tumor endothelium.
- Generation humanized immune-reconstituted (HIR) mice model to define a specific human gene signature of early pro-metastatic niche.

Dr. Stefano Ugel skills are:

- Cellular Biology: human and murine cellular culture, proliferation and cytotoxicity assays, lymphocytes isolation from spleens and tumors, in particular derivation of specific antigen CTL, transfection of cells to induce specific antigen expression, ELISA assays, ELISpot assays, cytofluorimetric analysis, such as intracytoplasmatic analysis of IFN $\gamma$ . Evaluation of immune response after vaccination in mouse models in particular in prostate and melanoma tumor models. Phenotypic characterization and isolation by immunomagnetic sorting of specific cells.
- Molecular Biology: RNA and DNA extraction from different tissues, PCR, RT-PCR, Real Time PCR, gene cloning, western blot, protein purification in particular antibodies. Experience of gene expression by Affymetrix.
- Mouse handling.
- Computer skills and competences of Microsoft office tools (word, excel, power point) and also basic knowledge of graphic design applications (CorelDraw, CorelPhotoPaint, SigmaPlot, FlowJo).
- Technical practice of specific laboratory instruments: FACS CANTO, Elipot-Reader and BTX electroporator.
- Knowledge of English language.

## CONGRESS ABSTRACT

- Cingarlini S., **Ugel S.**, Marigo I., De Santo C., Dolcetti L., Gallina G., Bronte V., and Zanovello P. *Preserved effective Env responsiveness in TRAMP mice*. SIICA, Ischia (Italia); 2005. **Selezionato per presentazione orale.**

- **Ugel S.**; Cingarlini S.; Mesa Pardillo C.; Cipriani B.; Mennuni C.; Cerino R.; Calvaruso F.; Scarselli E.; Iezzi M.; Musiani P.; Zanovello P. and Bronte V. *Induction of telomerase-specific cytotoxic T cells by recombinant vaccines*. SIC, Bari (Italia); 2006.
- Gallina G., Dolcetti L., Serafini P., De Santo C., Marigo I., Cingarlini S., **Ugel S.**, Colombo M.P., Basso G., Brombacher F., Borrello I., Zanovello P., Bicciato S. and Bronte V. *Tumor-induced IL-4R $\alpha$ <sup>+</sup> inflammatory monocytes with immunosuppressive activity on CD8<sup>+</sup> T cells*. SIICA, Parigi (Francia); 2006.
- Dolcetti L., Gallina G., De Santo C., Marigo I., Serafini P., Cingarlini S., **Ugel S.**, Colombo M.P., Basso G., Brombacher F., Borrello I., Zanovello P., Bicciato S. and Bronte V. *IL-4R $\alpha$ <sup>+</sup> is a marker of a subset cells of inflammatory monocytes with immunosuppressive activity on CD8<sup>+</sup> T cells*. The Potent New Anti-Tumor Immunotherapies. Keystone Symposia on Molecular Biology, Fairmont Banff Springs. Banff (Alberta); 2007
- **Ugel S.**, Peranzoni E., Marigo I., Dolcetti L., Sonda N., Mantelli B., Papalini F., Zilio S., Mennuni C., Scarselli E., De Palma R., Zanovello P., and Bronte V. *Adoptive immunotherapy for cancer based on mTERT specific CD8<sup>+</sup> T cells*. SIICA, Roma (Italia), 2008.
- Marigo I., Fernandez-Gomez A., Mandruzzato S., Francescato S., Valpione S., Perini P., Rinaldi L., Gallo P., **Ugel S.**, Zanovello P. and Bronte V. *MDSC: potential therapeutic role in autoimmune diseases*. FISM Synphosia, Roma (Italia), 2008. **Selezionato per presentazione orale**
- Martini M., Testi M.G., Pasetto M., Picchio M.C., Innamorati G., Mazzocco M., **Ugel S.**, Cingarlini, Bronte V., Zanovello P., Krampera M., Mosna F., Cestari T., Riviera A.P., Brutti N., Barbieri O., Matera L., Tridente G., Colombatti M. and Sartoris S. *IFN- $\gamma$  mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer*. 2nd European Congress of Immunology Berlino (Germania), 2009
- Dolcetti L., Peranzoni E., **Ugel S.**, Marigo I., Fernandez Gomez A., Mesa C., Geilich M., Winkels G., Traggiati E., Casati A., Grassi F. and Bronte V. *Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF*. 2nd European Congress of Immunology Berlino (Germania), 2009. **Selezionato per presentazione orale**
- **Ugel S.**, Rueter J., De Sanctis F., Scarselli E., Mennuni C., La Monica N., Coukos G. and Facciabene A. *mTERT genetic vaccine combined with chemotherapy augments antigen-specific immune response and confers tumor protection in time depended fashion*. Gene Vaccination in Cancer, Ascoli Piceno (Italia), 2011
- **Ugel S.**, Peranzoni E., Desantis G., Chioda M., Walter S., Weinschenk T., Ochando J.C., Cabrelle A., Mandruzzato S. and Bronte V. *Immune tolerance to tumor antigens occurs in a specialized environment of the spleen..* SIC, Bologna (Italia), 2012.
- Sandri S., Bobisse S., Moxley K., Lamolinara A., De Sanctis F., Boschi F., Sbarbati A., Fracasso G., Ferrarini G., Hendriks R.W., Cavallini C., Scupoli M.T., Sartoris S., Iezzi M., Nishimura M.I., Bronte V.\* and **Ugel S.\*** *Anti-telomerase adoptive cell therapy to target B-cell lymphocytic leukemia*. CIMT, Mainz (Germania), 2013.
- De Sanctis F., **Ugel S.**, Fassan M., Iezzi M., Boschi F., Youngkyu P., Stramucci L., Lamolinara A., Sandri S., Ferrarini G., Cristovao Borges L., Sartoris S., Sbarbati A., Tuveson D., Scarpa A. e Bronte V. *Targeting telomerase in pancreatic cancer*. NIBIT, Siena (Italia), 2014.
- **Ugel S.**, Facciponte J.G., De Sanctis F., Li C, Wang L., Nair G., Sehgal S., Raj A. ,Matthaiou E., Coukos G. and Facciabene A. *Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature*. NIBIT, Siena (Italia), 2014.
- Sandri S., Bobisse S., Moxley K., Lamolinara A., De Sanctis F., Boschi F., Sbarbati A., Fracasso G., Ferrarini G., Hendriks R.W., Cavallini C., Scupoli M.T., Sartoris S., Iezzi M., Nishimura M.I., Bronte V.\* and **Ugel S.\*** *Targeting B-cell lymphocytic leukemia by adoptive transfer of telomerase specific T cells*. PIVAC, Roma (Italia), 2014. **Poster premiato con**

**encomia** vedi: Signori E, Cavallo F. *The Fourteenth International Conference on Progress in Vaccination Against Cancer (PIVAC-14), September 24-26, 2014, Rome, Italy: rethinking anti-tumor vaccines in a new era of cancer immunotherapy.* Cancer Immunol Immunother. 2015

- Sandri S., Bobisse S., Moxley K., Lamolinara A., De Sanctis F., Boschi F., Sbarbati A., Fracasso G., Ferrarini G., Hendriks R.W., Cavallini C., Scupoli M.T., Sartoris S., Iezzi M., Nishimura M.I., Bronte V.\* and **Ugel S.\*** *Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies.* CMIT, Mainz (Germania), 2016
- Trovato R., De Sanctis F., Fiore A., Sandri S., Sartori S., Poffe O., Anselmi C., Fracasso G., Iezzi M., Lamolinara A., Fassan M., Rusev B., Scarpa A., Boschi F., Ruggeri L., Tuveson D., Sartoris S., **Ugel S.** and Bronte V. *Tumor-infiltrating myeloid cells in pancreatic ductal adenocarcinoma.* Regulatory Myeloid-Suppressor Cell Conference, Philadelphia (USA), 2016.
- De Sanctis F., Fassan M., Lamolinara A., Iezzi M., Boschi F., Sbarbati A., Youngkyu P., Sandri S., Trovato R., Fiore A., Sartori S., Poffe O., Fracasso G., Anselmi C., Tuveson D., Lawlor R.T., Scarpa A., Sartoris S., **Ugel S.** and Bronte V. *Telomerase specific adoptive cell therapy in pancreatic cancer.* NIBIT, Verona (Italia), 2016.

## INVITED LECTURES AND PRESENTATIONS

- **Ugel S.**, Mennuni C., Mori F., Cipriani B., Iezzi M., Pannellini T., Lazzaro D., Ciliberto G., La Monica N., Zanovello P., Bronte V., and Scarselli E. *Immunosurveillance by telomerase-based vaccination.* SIICA, Roma (Italy), 2008.
- **Ugel S.**, Peranzoni E, Piccoli M, Falisi E, Papalini F, Solito S, Cabrelle A, De Coppi P, Zanovello P, Mandruzzato S and Bronte V. *Rational and successful chemo-immunotherapy: unveiling a novel immune adjuvant property of chemotherapeutic drugs based on the perturbation of myeloid suppressor biological niche.* SIICA, Bari (Italy), 2010.
- **Ugel S.**, Facciponti J., De Sanctis F., Mitrousis N., Wang L., Nair G., Coukos G. and Facciabene A. *Gene based vaccination specific for TEM1 (Endosialin/CD248) controls tumor progression inducing a specific T cell response.* Gene Vaccination in Cancer, Ascoli Piceno (Italy), 2011.
- **Ugel S.**, Rueter J., De Sanctis F., Scarselli E., Mennuni C., La Monica N., Coukos G. and Facciabene A. *mTERT genetic vaccine combined with chemotherapy augments antigen-specific immune response and confers tumor protection in time depended fashion.* TRCCC, Seven Springs (USA), 2012.
- **Ugel S.** *Overcoming Physical Barriers to Cancer Immunotherapy.* 2<sup>nd</sup> Inflammation, Cancer and Novel Therapeutics Conference & Summer School 2012. Heraklion, Creta (Greece), 2012.
- **Ugel S.**, Peranzoni E., Desantis G., Chioda M., Walter S., Weinschenk T., Ochando J.C., Cabrelle A., Mandruzzato S. and Bronte V. *Myeloid Derived Suppressive Cells: Overcoming Physical Barriers to Cancer Immunotherapy.* InsPiRE Conference "Progress in combination therapy in cancer using novel immunomodulators", Atene (Greece), 2012.
- **Ugel S.** *Modulation of tumor microenvironment by chemotherapy.* 10<sup>th</sup> Annual Meeting, NIBIT, Certosa di Pontignano (SI) (Italy), 2012

## AWARDS AND HONORS

- November 2006: Winner of the Prize "Laura Polo" for best bachelor thesis in Oncology awarded by the University of Padova, Italy.
- August 2010: Winner winner of Start-Up Veneto 2010 "La note degli angeli" with the scientific group Safespring of University of Padova to develop an innovative technology to make water drinkable.

- September 2011: Winner of the prize as best poster of under-35 researcher awarded by Gene Vaccination in Cancer, Ascoli Piceno (Italy)
- September 2014: Winner of prize as best poster (as special mention) of under-35 research awarded by EACR at 14<sup>th</sup> International Conference on Progress in Vaccination Against Cancer (PIVAC-14), Rome (Italy) as testified by publication published in Cancer Immunol Immunother. 2015, 64(10):1349-56

## **PATENT**

- 2015: **Ugel S.**, Sandri S., Bobisse S., Bronte V. Gene sequence encoding a mouse TCR specific for the human HLA-A2 complex and hTERT865-873 peptide and its use for engineering human T lymphocytes for adoptive cell therapy of cancer. University of Verona, 102015902339333 (PD2015A000062).
- 2017: **Ugel S.**, Fiore A., Sahin U. and Bronte V. Engineered cells for inducing tolerance. Biontech (Mainz, DE), PCT/EP2017/051068.

## **DIDATIC WORK**

2016-up now: Professor of Immunology at course of Bachelor's degree in Biomedical Laboratory Techniques (to qualify as a biomedical laboratory worker);

2016-up now: Professor of Immunology at course of Combined Bachelor's + Master's degree in Dentistry and Dental Prosthetics;

2017-up now: Professor of Sciences introduction to the medical profession at course of Combined Bachelor's + Master's degree in Medicine and Surgery;

2017-up now: Professor of Systematic pathology I at course of Combined Bachelor's + Master's degree in Medicine and Surgery;

Tutor activity's of Dr. Stefano Ugel is testified:

- 2008: Assistant supervisor of Dr.ssa Biondani Pamela bachelor degree (summa cum laude) in Surgical and Medical Sciences at University of Padova (Italy);
- 2009: Assistant supervisor of Dr.ssa Sara Bisetto bachelor degree (108/110) in Pharmacology at University of Padova (Italy);
- 2012-2014: Supervisor of Dr.ssa Ferrarini Giovanna PhD-program in Translational Medicine at University of Verona (Italy);
- 2014: Assistant supervisor of Dr.ssa Cristovao Borges Lorena bachelor degree (102/110) in Biotechnology at University of Verona (Italy);
- 2014: Assistant supervisor of Dr. Daniele Pellegrini bachelor degree (98/110) in Biotechnology at University of Verona (Italy);
- 2015: Assistant supervisor of Dr. Barbara Zerbato bachelor degree (100/110) in Biotechnology at University of Verona (Italy);
- 2015: Assistant supervisor of Dr. Giulia Barban bachelor degree (106/110) in Biotechnology at University of Verona (Italy);

- 2017: Assistant supervisor of Dr. Lorenzo Bombarda bachelor degree (90/110) in Biotechnology at University of Verona (Italy);

## BOOKS

- De Sanctis F., Bronte V, **Ugel S.** *Tumor-induced Myeloid-derived Suppressor Cells*. In: *Myeloid Cells in Health and Disease: A Synthesis*, 2015, ASM Press.

## PUBLICATION

1. Mondanelli G., **Ugel S.**, Grohmann U., Bronte V. *The immune regulation in cancer by the amino acid metabolizing enzymes ARG and IDO*. Curr Opin Pharmacol. 2017 May 26;35:30-39. doi: 10.1016/j.coph.2017.05.002. PMID: 28554057
2. Giardino A., Innamorati G., **Ugel S.**, Perbellini O., Girelli R., Frigerio I., Regi P., Scopelliti F., Butturini G., Paiella S., Bacchion M., Bassi C. *Immunomodulation after radiofrequency ablation of locally advanced pancreatic cancer by monitoring the immune response in 10 patients*. Pancreatology. 2017 Sep 27. pii: S1424-3903(17)30851-7. doi: 10.1016/j.pan.2017.09.008. PMID: 29037917
3. Mondanelli G., Bianchi R., Pallotta M.T., Orabona C., Albin E., Iacono A., Belladonna M.L., Vacca C., Fallarino F., Macchiarulo A., **Ugel S.**, Bronte V., Gevi F., Zolla L., Verhaar A., Peppelenbosch M., Mazza E.M., Bicciato S., Laouar Y., Santambrogio L., Puccetti P., Volpi C. and Grohmann U. *A Relay Pathway between Arginine and Tryptophan Metabolism Confers Immunosuppressive Properties on Dendritic Cells*. Immunity. 2017 Feb 21;46(2):233-244. doi: 10.1016/j.immuni.2017.01.005. Epub 2017 Feb 14. PMID: 28214225
4. Malpeli G., Barbi S., Zupo S., Tosadori G., Scardoni G., Bertolaso A., Sartoris S., **Ugel S.**, Vicentini C., Fassan M., Adamo A., Krampera M., Scupoli M.T., Croce C.M. and Scarpa A. *Identification of microRNAs implicated in the late differentiation stages of normal B cells suggests a central role for miRNA targets ZEB1 and TP53*. Oncotarget. 2017 Feb 14;8(7):11809-11826. doi: 10.18632/oncotarget.14683. PMID: 28107180
5. Marigo I., Zilio S., Desantis G., Mlecnik B., Agnellini A.H., **Ugel S.**, Sasso M.S., Qualls J.E., Kratochvill F., Zanovello P., Molon B., Ries C.H., Runza V., Hoves S., Bilocq A.M., Bindea G., Mazza E.M., Bicciato S., Galon J., Murray P.J. and Bronte V. *T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells*. Cancer Cell. 2016 Sep 12;30(3):377-90. doi: 10.1016/j.ccell.2016.08.004. PMID: 27622331
6. De Sanctis F., Bronte V. and **Ugel S.** *Tumor-Induced Myeloid-Derived Suppressor Cells*. Microbiol Spectr. 2016 Jun;4(3). doi: 10.1128/microbiolspec.MCHD-0016-2015. PMID:27337449.
7. Sandri S., Bobisse S., Moxley K., Lamolinara A., De Sanctis F., Boschi F., Sbarbati A., Fracasso G., Ferrarini G., Hendriks R.W., Cavallini C., Scupoli M.T., Sartoris S., Iezzi M., Nishimura M.I., Bronte V.\* and **Ugel S.\*** *Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell*

*Chronic Lymphocytic Leukemia and Solid Malignancies* Cancer Res. 2016 May 1;76(9):2540-51. doi: 10.1158/0008-5472.CAN-15-2318. PMID: 27197263. (\* equal contribution)

8. **Ugel S.**, De Sanctis F., Mandruzzato S. and Bronte V. *Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages.* J Clin Invest. 2015 Sep;125(9):3365-76. doi: 10.1172/JCI80006. Review. PMID: 26325033.
9. **Ugel S.\***, Facciponte J.G.\*, De Sanctis F. and Facciabene A. *Targeting tumor vasculature: expanding the potential of DNA cancer vaccines.* Cancer Immunol Immunother. 2015 Oct;64(10):1339-48. doi: 10.1007/s00262-015-1747-8. Review. PMID: 26267042. (\* equal contribution)
10. De Sanctis F., Solito S., **Ugel S.**, Molon B., Bronte V. And Marigo I. *MDSCs in cancer: Conceiving new prognostic and therapeutic targets.* Biochim Biophys Acta. 2016Jan;1865(1):35-48. doi: 10.1016/j.bbcan.2015.08.001. PMID: 26255541.
11. Mazzocco M., Martini M., Rosato A., Stefani E., Matucci A., Dalla Santa S., De Sanctis F., **Ugel S.**, Sandri S., Ferrarini G., Cestari T., Ferrari S., Zanovello P., Bronte V. and Sartoris S. *Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma.* Immunology. 2015 Sep;146(1):33-49. doi:10.1111/imm.12477. PMID: 25959091.
12. Ricci C., Mota C., Moscato S., D'Alessandro D., **Ugel S.**, Sartoris S., Bronte V., Boggi U., Campani D., Funel N., Moroni L. and Danti S. *Interfacing polymeric scaffolds with primary pancreatic ductal adenocarcinoma cells to develop 3D cancer models.* Biomatter. 2014;4:e955386. doi: 10.4161/21592527.2014.955386. PMID:25482337.
13. Facciponte J.G.\*, **Ugel S. \***, De Sanctis F., Li C, Wang L., Nair G., Sehgal S., Raj A. ,Matthaiou E., Coukos G. and Facciabene A. *Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature.* J Clin Invest. 2014 Apr;124(4):1497-511.doi: 10.1172/JCI67382. PMID: 24642465. (\* equal contribution)
14. De Sanctis F., Sandri S., Ferrarini G., Pagliarello I., Sartoris S., **Ugel S.**, Marigo I., Molon B. And Bronte V. *The emerging immunological role of post-translational modifications by reactive nitrogen species in cancer microenvironment.* Front Immunol. 2014 Feb 24;5:69. doi:10.3389/fimmu.2014.00069. eCollection 2014. Review. PubMed PMID: 24605112
15. **Ugel S.\***, Peranzoni E.\*, Desantis G., Chioda M., Walter S., Weinschenk T., Ochando J.C., Cabrelle A., Mandruzzato S. and Bronte V. *Immune tolerance to tumor antigens occurs in a specialized environment of the spleen.* Cell Rep. 2012 Sep 27;2(3):628-39. doi: 10.1016/j.celrep.2012.08.006. PMID: 22959433. (\* equal contribution)
16. Molon B.\*, **Ugel S.\***, Del Pozzo F., Soldani C., Zilio S., Avella D., De Palma A., Mauri P., Monegal A., Rescigno M., Savino B., Colombo P., Jonjic N., Pecanic S., Lazzarato L., Fruttero R., Gasco A., Bronte V. and Viola A. *Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells.* J Exp Med. 2011 Sep 26;208(10):1949-62.doi: 10.1084/jem.20101956. PMID: 21930770. (\* equal contribution)
17. Marigo I., Bosio E., Solito S., Mesa C., Fernandez A., Dolcetti L., **Ugel S.**, Sonda N., Biccato S., Falisi E., Calabrese F., Basso G., Zanovello P., Cozzi E., Mandruzzato S. and Bronte V. *Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription*

*factor*. Immunity. 2010 Jun 25;32(6):790-802. doi:10.1016/j.immuni.2010.05.010. PubMed PMID: 20605485.

18. Martini M., Testi M.G., Pasetto M., Picchio M.C., Innamorati G., Mazzocco M., **Ugel S.**, Cingarlini S., Bronte V., Zanovello P., Krampera M., Mosna F., Cestari T., Riviera A.P., Brutti N., Barbieri O., Matera L., Tridente G., Colombatti M. and Sartoris S. *IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer*. Vaccine. 2010 Apr 30;28(20):3548-57. doi:10.1016/j.vaccine.2010.03.007. PMID: 20304037.
19. Dolcetti L., Peranzoni E., **Ugel S.**, Marigo I., Fernandez Gomez A., Mesa C., Geilich M., Winkels G., Traggiai E., Casati A., Grassi F. and Bronte V. *Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF*. Eur J Immunol. 2010 Jan;40(1):22-35. doi:10.1002/eji.200939903. PMID: 19941314.
20. **Ugel S.\***, Zoso A.\*, De Santo C.\*, Li Y., Marigo I., Zanovello P., Scarselli E., Cipriani B., Oelke M., Schneck J.P. and Bronte V. *In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer*. Cancer Res. 2009 Dec 15;69(24):9376-84. doi: 10.1158/0008-5472.CAN-09-0400. PMID: 19934317. (\* equal contribution)
21. **Ugel S.\***, Scarselli E.\*, Iezzi M., Mennuni C., Pannellini T., Calvaruso F., Cipriani B., De Palma R., Ricci-Vitiani L., Peranzoni E., Musiani P., Zanovello P. and Bronte V. *Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes*. Blood. 2010 Feb 18;115(7):1374-84. doi:10.1182/blood-2009-07-233270. PMID: 19903903. (\* equal contribution)
22. **Ugel S.**, Delpozzo F., Desantis G., Papalini F., Simonato F., Sonda N., Zilio S. And Bronte V. *Therapeutic targeting of myeloid-derived suppressor cells*. Curr Opin Pharmacol. 2009 Aug;9(4):470-81. doi: 10.1016/j.coph.2009.06.014. Review. PMID: 19616475.
23. Mennuni C.\*, **Ugel S.\***, Mori F., Cipriani B., Iezzi M., Pannellini T., Lazzaro D., Ciliberto G., La Monica N., Zanovello P., Bronte V. and Scarselli E. *Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer*. Cancer Res. 2008 Dec 1;68(23):9865-74. doi: 10.1158/0008-5472.CAN-08-1603. PMID: 19047167. (\* equal contribution)
24. Peranzoni E., Marigo I., Dolcetti L., **Ugel S.**, Sonda N., Taschin E., Mantelli B., Bronte V. and Zanovello P. *Role of arginine metabolism in immunity and immunopathology*. Immunobiology. 2007;212(9-10):795-812. Review. PMID: 18086380.
25. Bronte V., Cingarlini S., Marigo I., De Santo C., Gallina G., Dolcetti L., **Ugel S.**, Peranzoni E., Mandruzzato S. and Zanovello P. *Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention*. Immunol Invest. 2006;35(3-4):327-57. Review. PMID: 16916757.



The scientific research activity of Dr. Stefano Ugel is proved by different bibliographic indexes:

SCOPUS:

Documenti: 27

Hirsch h index: 14

Citations: 1453

<https://www.scopus.com/>

Web of Science

Documenti: 26

Hirsch h index: 14

Citations: 1131

[http://apps.webofknowledge.com/WOS\\_GeneralSearch\\_input.do?product=WOS&search\\_mode=GeneralSearch&SID=Q2nhFMu6oynPK5ojF9M&preferencesSaved=](http://apps.webofknowledge.com/WOS_GeneralSearch_input.do?product=WOS&search_mode=GeneralSearch&SID=Q2nhFMu6oynPK5ojF9M&preferencesSaved=)

Firma

A handwritten signature in black ink, appearing to read 'Stefano Ugel', written in a cursive style with a large, sweeping flourish at the end.

Il sottoscritto è consapevole Stefano Ugel:

di essere penalmente sanzionabile se rilascia falsa dichiarazione (art. 76 D.P.R. 445/2000), di decadere dei benefici conseguiti di un provvedimento adottato sulla base delle false dichiarazioni art. 75 D.P.R. n. 445/2000; che l'amministrazione si riserva di controllare la veridicità delle dichiarazioni rese (art. 71 D.P.R. 445/2000); che i dati forniti dal dichiarante saranno utilizzati solo ai fini del procedimento richiesto (D.L. vo n. 0196/2003)

Firma

A handwritten signature in black ink, appearing to read 'Stefano Ugel', written in a cursive style with a large, sweeping flourish at the end.